过氧化物酶体增殖物激活受体γ激动剂在终末期肾脏病中的研究进展

Peroxisome proliferator-activated receptor gamma agonists in end stage renal disease

过氧化物酶体增殖物激活受体γ(PPAR-γ)是一种细胞核受体,除了能够调节机体糖脂代谢外,在抗炎、抗纤维化、调节免疫及抗动脉粥样硬化等方面也发挥着重要作用。终末期肾脏病(ESRD)患者由于疾病本身和肾脏替代治疗的介入常存在胰岛素抵抗和微炎症状态,心血管疾病的发病率和死亡率显著高于普通人群。新近关于PPAR-γ激动剂应用于ESRD的研究结果提示PPAR-γ激动剂能够改善ESRD患者上述病理生理。本文就这方面的研究进展以及目前有关热点问题进行综述。

Peroxisome proliferator-activated eceptor gamma （ PPAR-3, ） is a member of the steroid hormone nuclear receptor family which plays an important role in glucose metabolism, however, it also has beneficial effects on inflammation,fibration, immunization, atherosclerosis and so on. The renal damage resulted from all kinds of causes finally leads to end stage renal disease（ ESRD）which often accompanied with insulin resistant（IR） and minimal inflammation, and ESRD patients often have high cardiovascular morbidity and mortality because of toxin accumulation and problems associated with aheruate treatment. At present,some studies about PPAR-γ, agonists in ESRD have been reported. Moreover, these studies suggest that the PPAR-γ, agonists, Thiazolidinediones （TZDs）, may be a potential and effective drug in ESRD. We review herein recent advances on the role of PPAR-γ, agonists in ESRD,and the effects of PPAR-γ, agonists on cardiovascular system of ESRD patients.